Trevena has announced positive results from a proof-of-concept clinical trial during which its new AT1 receptor-selective agonist, TRV027, was found to be well-tolerated in Covid-19 patients who have been hospitalised.
Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years.
The US Food and Drug Administration (FDA) has declined Humanigen’s request for Emergency Use Authorization (EUA) of its antibody lenzilumab to treat newly hospitalised Covid-19 patients.
AIM ImmunoTech has submitted a pre-investigational new drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a study of Ampligen as a potential infusion treatment for post-Covid-19 cognitive dysfunction (PCCD).
The Drugs Controller General of India (DCGI) has given approval to Reliance Life Sciences to conduct a Phase I clinical trial of its Covid-19 vaccine with certain conditions.
Senhwa Biosciences has announced that its oral drug, Silmitasertib, has received positive feedback from an independent Data Monitoring Committee (DMC) in an interim review of Phase II investigator-initiated trial in patients with severe Covid-19.
Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern.
Inovio has secured approval from Center for Drug Evaluation of the National Medical Products Administration in China to carry out two clinical trials of heterologous prime-boosting with its Covid-19 vaccine candidate, INO-4800.
India has given approval to Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine for emergency use.
Akston Biosciences has initiated dosing of the first subjects in a Phase II open-label trial of AKS-452, its protein subunit Covid-19 vaccine candidate.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.